Floatz logo

TAURURSODIOL

Spinal Cord Diseases

Amylyx Pharmaceuticals Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Spinal Cord Diseases cohort.

Asset / SponsorPhaseRating
Oxybutynin
Astellas Pharma Inc
Phase 4BB
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3B
Marijuana
Barth Wilsey
Phase 2/3B
SOLIFENACIN
Astellas Pharma Inc
Phase 4B

Same molecule, other indications

TAURURSODIOL is also rated in:

amyotrophic lateral sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
64 / 100
View asset →
wild type ATTR amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →